NCT03889743 (INSTAR) is a Phase 4 clinical trial of Dexamethasone treatment during 3 days in Asthma, sponsored by St. Olavs Hospital.

Who is sponsoring NCT03889743?

NCT03889743 is sponsored by St. Olavs Hospital.

What drugs are being tested in NCT03889743?

Interventions in NCT03889743: Dexamethasone treatment during 3 days, placebo treatment during 3 days.

What condition does NCT03889743 study?

NCT03889743 studies Asthma, Inflammation.

Is NCT03889743 still recruiting?

NCT03889743 is currently recruiting now. Last updated 10 June 2025.

Last reviewed 2025-06-10 · How we verify

NCT03889743: INSTAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing - the INSTAR Study

Recruiting now Phase 4 Last updated 10 June 2025

What this trial tests

Phase 4 trial testing Dexamethasone treatment during 3 days in Asthma in 280 participants. Currently enrolling.

Timeline

8 May 2019

Primary endpoint
1 May 2028

1 May 2028

Quick facts

Lead sponsor	St. Olavs Hospital
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	280
Start date	8 May 2019
Primary completion	1 May 2028
Estimated completion	1 May 2028
Sites	8 locations across Finland, Norway, Sweden

Drugs / interventions tested

Dexamethasone treatment during 3 days — full drug profile →
placebo treatment during 3 days — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →
Inflammation — all drugs for Inflammation →

Sponsor

St. Olavs Hospital

Who can join

Adults 3 Months to 23 Months, any sex, with Asthma or Inflammation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

time to a new physician-confirmed wheezy episode within 24 months after study entry
Time frame: 24 months
time to need for a regular controller medication for asthma within 24 months after study entry
Time frame: 24 months

Sponsor's own description

The overall objective of the study is to determine the efficacy of corticosteroids in preventing recurrent wheezing and asthma in high-risk, first-time severe wheezing children with rhinovirus infection, stratified by rhinovirus genome load. The secondary objectives are to determine duration and severity of each acute episode with acute expiratory breathing difficulty, the number of episodes with acute expiratory breathing difficulty, degree of pulmonary hyperreactivity and quality of life within 24 months after study entry.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

INnovative Steroid Treatment to reduce Asthma development in children after first-time Rhinovirus-induced wheezing (INSTAR): protocol for a randomised placebo-controlled trial.
Elvebakk T, Døllner H, Partty A, Jartti H, et al · · 2025 · PMID 40738645 · DOI 10.1136/bmjopen-2025-103530

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other St. Olavs Hospital trials

Trials by the same sponsor.

NCT07331766 — Collaboratory Treatment Pathway for Chronic Pain Patients. · NA · enrolling by invitation
NCT07305025 — Pelvic Pain Electro-Acupuncture · NA · not yet recruiting
NCT07245264 — Adjuvant Tranexamic Acid (TXA) Versus Surgery Alone for Adult Patients With Chronic Subdural Hematoma (CSDH) · Phase 2, PHASE3 · recruiting
NCT07180433 — Piloting 18F-FAPI PET/MRI for Applications in Breast Cancer · NA · not yet recruiting
NCT06854861 — Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes · Phase 1, PHASE2 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03889743 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Olavs Hospital
Last refreshed: 10 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03889743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing